Sarepta Therapeutics Inc (SRPT)
127.97
+2.96
(+2.37%)
USD |
NASDAQ |
Nov 06, 16:00
124.53
-3.44
(-2.69%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 12.20B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 59.76% |
Valuation | |
PE Ratio | 172.93 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 8.310 |
Price to Book Value | 11.33 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 1.139 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 64.93% |
Profile
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development. |
URL | https://www.sarepta.com |
Investor Relations URL | https://investorrelations.sarepta.com |
HQ State/Province | Massachusetts |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Feb. 28, 2025 (est.) |
Last Earnings Release | Nov. 06, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development. |
URL | https://www.sarepta.com |
Investor Relations URL | https://investorrelations.sarepta.com |
HQ State/Province | Massachusetts |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Feb. 28, 2025 (est.) |
Last Earnings Release | Nov. 06, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |